Cargando…

Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre

Flash glucose monitoring (FGM) and real-time continuous glucose monitoring (RT-CGM) are increasingly used in clinical practice, with improvements in HbA1c and time in range (TIR) reported in clinical studies. We aimed to evaluate the impact of FGM and RT-CGM use on glycaemic outcomes in adults with...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Kyuhan, Gunasinghe, Shakthi, Chapman, Alyson, Findlow, Lynne A., Hyland, Jody, Ohol, Sheetal, Urwin, Andrea, Rutter, Martin K., Schofield, Jonathan, Thabit, Hood, Leelarathna, Lalantha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615559/
https://www.ncbi.nlm.nih.gov/pubmed/34821673
http://dx.doi.org/10.3390/bios11110457
_version_ 1784604133718753280
author Lee, Kyuhan
Gunasinghe, Shakthi
Chapman, Alyson
Findlow, Lynne A.
Hyland, Jody
Ohol, Sheetal
Urwin, Andrea
Rutter, Martin K.
Schofield, Jonathan
Thabit, Hood
Leelarathna, Lalantha
author_facet Lee, Kyuhan
Gunasinghe, Shakthi
Chapman, Alyson
Findlow, Lynne A.
Hyland, Jody
Ohol, Sheetal
Urwin, Andrea
Rutter, Martin K.
Schofield, Jonathan
Thabit, Hood
Leelarathna, Lalantha
author_sort Lee, Kyuhan
collection PubMed
description Flash glucose monitoring (FGM) and real-time continuous glucose monitoring (RT-CGM) are increasingly used in clinical practice, with improvements in HbA1c and time in range (TIR) reported in clinical studies. We aimed to evaluate the impact of FGM and RT-CGM use on glycaemic outcomes in adults with type 1 diabetes (T1DM) under routine clinical care. We performed a retrospective data analysis from electronic outpatient records and proprietary web-based glucose monitoring platforms. We measured HbA1c (pre-sensor vs. on-sensor data) and sensor-based outcomes from the previous three months as per the international consensus on RT-CGM reporting guidelines. Amongst the 789 adults with T1DM, HbA1c level decreased from 61.0 (54.0, 71.0) mmol/mol to 57 (49, 65.8) mmol/mol in 561 people using FGM, and from 60.0 (50.0, 70.0) mmol/mol to 58.8 (50.3, 66.8) mmol/mol in 198 using RT-CGM (p < 0.001 for both). We found that 23% of FGM users and 32% of RT-CGM users achieved a time-in-range (TIR) (3.9 to 10 mmol/L) of >70%. For time-below-range (TBR) < 4 mmol/L, 70% of RT-CGM users and 58% of FGM users met international recommendations of <4%. Our data add to the growing body of evidence supporting the use of FGM and RT-CGM in T1DM.
format Online
Article
Text
id pubmed-8615559
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86155592021-11-26 Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre Lee, Kyuhan Gunasinghe, Shakthi Chapman, Alyson Findlow, Lynne A. Hyland, Jody Ohol, Sheetal Urwin, Andrea Rutter, Martin K. Schofield, Jonathan Thabit, Hood Leelarathna, Lalantha Biosensors (Basel) Article Flash glucose monitoring (FGM) and real-time continuous glucose monitoring (RT-CGM) are increasingly used in clinical practice, with improvements in HbA1c and time in range (TIR) reported in clinical studies. We aimed to evaluate the impact of FGM and RT-CGM use on glycaemic outcomes in adults with type 1 diabetes (T1DM) under routine clinical care. We performed a retrospective data analysis from electronic outpatient records and proprietary web-based glucose monitoring platforms. We measured HbA1c (pre-sensor vs. on-sensor data) and sensor-based outcomes from the previous three months as per the international consensus on RT-CGM reporting guidelines. Amongst the 789 adults with T1DM, HbA1c level decreased from 61.0 (54.0, 71.0) mmol/mol to 57 (49, 65.8) mmol/mol in 561 people using FGM, and from 60.0 (50.0, 70.0) mmol/mol to 58.8 (50.3, 66.8) mmol/mol in 198 using RT-CGM (p < 0.001 for both). We found that 23% of FGM users and 32% of RT-CGM users achieved a time-in-range (TIR) (3.9 to 10 mmol/L) of >70%. For time-below-range (TBR) < 4 mmol/L, 70% of RT-CGM users and 58% of FGM users met international recommendations of <4%. Our data add to the growing body of evidence supporting the use of FGM and RT-CGM in T1DM. MDPI 2021-11-15 /pmc/articles/PMC8615559/ /pubmed/34821673 http://dx.doi.org/10.3390/bios11110457 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lee, Kyuhan
Gunasinghe, Shakthi
Chapman, Alyson
Findlow, Lynne A.
Hyland, Jody
Ohol, Sheetal
Urwin, Andrea
Rutter, Martin K.
Schofield, Jonathan
Thabit, Hood
Leelarathna, Lalantha
Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre
title Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre
title_full Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre
title_fullStr Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre
title_full_unstemmed Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre
title_short Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre
title_sort real-world outcomes of glucose sensor use in type 1 diabetes—findings from a large uk centre
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615559/
https://www.ncbi.nlm.nih.gov/pubmed/34821673
http://dx.doi.org/10.3390/bios11110457
work_keys_str_mv AT leekyuhan realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre
AT gunasingheshakthi realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre
AT chapmanalyson realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre
AT findlowlynnea realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre
AT hylandjody realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre
AT oholsheetal realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre
AT urwinandrea realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre
AT ruttermartink realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre
AT schofieldjonathan realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre
AT thabithood realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre
AT leelarathnalalantha realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre